Peter Attia MD274 - Performance-enhancing drugs and hormones—risks, rewards, & broader implications for the public
CHAPTERS
- 0:00 – 10:29
Derek's Early Bodybuilding and Anabolic Steroid Experimentation
Derek Munro describes getting into lifting in high school, learning about steroids from underground forums, and reaching 260 pounds with sleep apnea. He and Peter Attia compare his doses of 1,500 mg to 2 g a week with the roughly 150 mg a week used in physiologic TRT.
- •Munro started lifting in grade 11 and became deeply interested in hormones and pharmacology
- •Information came largely from anecdotal underground forums
- •He reached 260-plus pounds and developed sleep apnea, his first taste of side effects
- •His peak dose was far above physiologic TRT, with sharply diminishing returns
- •Side-effect management in his early 20s relied on arbitrary bro rules
- 10:29 – 16:15
Underground Labs, Quality Control, and Post-Cycle Therapy Myths
Munro explains how underground labs source raw material and have little quality control, and Attia contrasts this with GMP and compounding-pharmacy disasters. They then discuss how few bodybuilders considered fertility and the arbitrary PCT regimens of the time.
- •Underground labs are cheap, and quality control often amounts to forum reputation or occasional third-party HPLC testing
- •Attia describes a fungal meningitis outbreak from compounded injectables as an example of the stakes
- •Anabolic harms are chronic rather than acute, so lab quality problems went unnoticed
- •The PCT rule of thumb was to stop, wait two weeks, then run Nolvadex and Clomid, often without checking blood work
- •Clomid doses were typically 25-50 mg once or twice a day
- 16:15 – 18:13
From Business Degree to Online Content Creation
Munro explains that he studied business at Simon Fraser University while working as a bouncer, then moved into online content. He started with a WordPress blog on diet and bodybuilding and expanded into anabolics and side-effect management.
- •He studied business, planning to become an accountant
- •He worked as a bouncer and then replaced that income through online posting
- •He started with a WordPress blog on diet, bulking, cutting and dating
- •The content later expanded to his experience with anabolics and side-effect management
- 18:13 – 27:02
Munro's Own GH Use and Growth Hormone for Height
Munro recounts trying GH at up to 6-8 IU a day without noticing much, and notes that GH drives bodybuilders' costs. Attia describes a parent asking about GH for a short 12-year-old tennis player, and Munro raises adult limb-lengthening surgery.
- •Munro found GH variable and conflated with water retention, and thought it too costly to continue
- •Attia says the literature on GH outside its medical use is narrow, so bodybuilder observations matter
- •Munro says idiopathic short stature protocols use even higher doses than GH deficiency
- •Attia's concern about GH in a child was unknown bone-quality risk
- •Munro describes surgeries that stretch bone for added height as a sign of how extreme some people go
- 27:02 – 41:43
Growth Hormone as an Elixir of Life and GH/IGF-1 Physiology
Attia describes longevity clinics that sell GH as an elixir and says he can't find an evidence-based view either way. Munro explains what GH does, how IGF-1 serves as the proxy for dosing, and how somatostatin, ghrelin and GHRH regulate GH output.
- •Attia sits between the claim that GH is dangerous and the claim that everyone should take it, for lack of evidence
- •GH matters for growth in adolescence and falls with age, but cannot lengthen bones after epiphyseal plate closure
- •GH is pulsatile, so IGF-1 is used as the proxy and the basis for dosing
- •Negative feedback from IGF-1 and somatostatin suppresses endogenous GH
- •Ghrelin receptor agonists and GHRH act through different pathways and are often combined
- 41:43 – 51:46
GH Suppression and Recovery, Healing, and Bone Health
Munro says the pituitary appears to recover after exogenous GH, unlike testicular function after testosterone. The discussion then covers GH for tissue repair after injury, Attia's brief nandrolone and GH trial before shoulder surgery, and its possible role in osteopenia.
- •Exogenous GH suppresses endogenous output, but the pituitary seems to bounce back
- •Evidence for GH in orthopedic rehabilitation is anecdotal and lacks counterfactuals
- •Attia stopped his nandrolone and GH trial after a week when he felt unwell
- •Munro says baseline IGF-1, diet and context should guide whether GH makes sense
- •Munro considers GH justified for bone health in someone with low IGF-1
- 51:46 – 1:07:12
Growth Hormone-Releasing Peptides and Their Regulatory Gray Zone
Munro sorts GH-releasing peptides into GHRP and GHRH classes, covering MK-677, ipamorelin, GHRP-6, tesamorelin, sermorelin and CJC-1295. They also discuss costs, unclear FDA status, compounding pharmacies, and how peptides compare with recombinant GH.
- •GHRPs act on the ghrelin receptor and GHRHs on the GHRH receptor, and appetite effects vary widely
- •MK-677 drives extreme hunger, while ipamorelin is most prescribed in clinics
- •Tesamorelin plus ipamorelin is a common clinic combination
- •Many of these compounds lack FDA approval or sit in a regulatory gray area
- •Peptides push endogenous production, while recombinant GH gives a manually chosen IGF-1 level but suppresses other GH variants
- 1:07:12 – 1:15:47
GH for Muscle, Fat Loss, Sleep and Lethargy
Munro says the evidence for GH building muscle or improving performance is thin, while fat liberation and body recomposition are more reliable. They discuss insulin resistance, dosing, GH's tie to deep sleep, daytime lethargy, and bodybuilders' super-physiologic IGF-1 targets.
- •Literature on GH and muscle growth or performance is sparse, and some gains may be water
- •Lipolysis is the more reproducible effect, with acute insulin resistance
- •Munro found high doses lethargy-inducing around the clock
- •GH is linked to deep sleep and may improve sleep quality
- •Clinics favor peptides on cost, while underground bodybuilders chase IGF-1 of 500 and above
- 1:15:47 – 1:33:15
Evolution of Bodybuilding Drug Use and the Distended Abdomen
Attia asks about the change between 1970s and modern physiques, and Munro ranks drugs first, then nutrition, then training. They debate whether '70s bodybuilders understated their doses and why GH and insulin arrived later. They then discuss protruding abdomens as a mix of food volume, gut issues and possible organ growth.
- •Munro ranks drugs above nutrition and training as drivers of modern physiques
- •He doubts the low doses reported by '70s bodybuilders
- •The late '80s and '90s saw GH and insulin use plus dose escalation
- •Abdominal distension is likely multifactorial, mostly huge food intake and GI problems
- •Attia notes that organ volumes could be measured with MRI
- 1:33:15 – 1:42:17
Deaths of Bodybuilders and Whole-Body MRI
Munro and Attia discuss deaths of young bodybuilders and the cardiovascular findings in autopsies, including enlarged hearts. They also cover the Jo Lindner case, with Attia declining to speculate, and talk about whole-body MRI for aneurysms.
- •Munro notes that Jo Lindner died at 30 despite frequent blood work
- •Attia declines to speculate without an autopsy
- •Autopsies of young bodybuilders mostly show cardiovascular problems, such as heart weights of 660 g and 860 g
- •Polypharmacy and stimulant use make causes hard to disentangle
- •Attia says whole-body MRI can reveal aneurysms, and shares his own approach to DVT prevention on flights
- 1:42:17 – 1:53:36
HPG Axis, Testosterone Metabolites, and DHT
Munro explains the hypothalamic-pituitary-testicular axis, feedback by androgen and estrogen receptors, and testosterone's conversion to DHT and estradiol. They distinguish androgenic from anabolic effects and discuss DHT's role after puberty.
- •GnRH drives LH and FSH, which act on Leydig and Sertoli cells, and receptor activation provides negative feedback
- •Testosterone converts to DHT via 5-alpha reductase and to estradiol via aromatase, with fat tissue increasing aromatase
- •DHT is the most androgenic hormone, while androgenic does not equal anabolic
- •Blocking DHT before puberty would prevent full maturation
- •Attia reviews androgen receptor binding and transcription
- 1:53:36 – 2:14:01
5-Alpha Reductase Inhibitors, Post-Finasteride Syndrome, and Munro's Hair Loss Treatment
Attia and Munro discuss finasteride, dutasteride and post-finasteride syndrome, comparing hair loss options such as minoxidil. Munro describes how he treated his own hair loss with lower doses, a 5-ARI and a topical anti-androgen, and why starting early matters.
- •Attia says post-finasteride syndrome is debated and he wouldn't start someone on a 5-ARI
- •Munro finds side-effect prevalence overblown but not nothing, and says minoxidil does not stop further loss
- •He reduced his androgen dose, used finasteride and then dutasteride, and used topical RU58841
- •He takes 0.5 mg dutasteride daily now, for convenience
- •Regrowth is harder than prevention, so waiting risks permanent loss
- 2:14:01 – 2:28:56
Testosterone Replacement Therapy: Indications, Dosing, and Injection Frequency
The pair discuss normal testosterone decline with age and the strongest case for TRT, primary hypogonadism. They cover starting doses, weekly versus more frequent injections, Natesto, cypionate versus enanthate, and subcutaneous versus intramuscular delivery.
- •Total T falls about 1% a year and free T 2-3%, but many men keep good levels
- •Primary hypogonadism is the clearest indication, and low LH and FSH point to lifestyle causes
- •A starting dose of about 80-120 mg a week is described as reasonable
- •More frequent dosing smooths peaks and can reduce aromatization and side effects
- •Enanthate pens are once weekly, and both favor twice-weekly or more frequent dosing
- 2:28:56 – 2:34:37
Estrogen in Men, Aromatase Inhibitors, and Hormone Testing Accuracy
Attia cites a study showing the best outcomes with high testosterone and high estrogen, and Munro explains why crushing estradiol is outdated. They cover estrogen's role in brain, heart and bone, and how immunoassays can misread estradiol compared with LC-MS.
- •The NEJM study found the best outcomes in the high-T, high-E group
- •Munro calls crushing estradiol to a reference range old bro lore
- •Estrogen matters for cardiovascular, neurological and bone health
- •5-ARIs raise estradiol by about 15-22%
- •Enzyme-based assays can wildly overestimate estradiol compared with LC-MS
- 2:34:37 – 3:04:12
Other Hormones, Anabolic Steroid History, SARMs, and Bodybuilder Regimens
They discuss hormones beyond testosterone, the history of anabolic derivatives, and the failed attempt to separate anabolic from androgenic effects. Munro covers SARMs, Tren, Deca and why testosterone remains the base, plus how top bodybuilders cycle drugs and how steroids confuse hormone testing.
- •Adrenal hormones and progesterone may suit some individuals, and Attia describes using oxandrolone to lower SHBG
- •Anabolic compounds were developed for muscle wasting and never fully separated anabolic from androgenic action
- •SARMs are more selective but have a lower anabolic ceiling
- •Testosterone stays the base because it provides aromatization and an estrogen layer
- •Top bodybuilders are on steroids 90-100% of the time and often need gynecomastia surgery
- •Cross-reactivity in immunoassays can mask suppression
- 3:04:12 – 3:24:25
Clomid, hCG, Enclomiphene, and Fertility Considerations
Munro explains hCG as an LH mimic and Clomid as a SERM acting at the hypothalamus, including the enclomiphene and zuclomiphene isomers. They compare fertility outcomes of testosterone versus hCG, hCG dosing, and the intratesticular androgen signal behind spermatogenesis.
- •hCG replaces LH to prevent testicular atrophy and maintain fertility
- •Clomid tricks the brain into making more testosterone, but central estrogen antagonism has costs, per Attia and Munro
- •A man maintained on hCG likely recovers more easily than one on testosterone alone
- •A study suggests FSH suppression comes from testosterone and estrogen feedback, not the LH receptor
- •Intratesticular androgen signaling is the main determinant of spermatogenesis, and 5-ARIs lower fertility
- 3:24:25 – 3:30:34
BPC-157 and Plans for a Second Conversation
Munro describes BPC-157 as an angiogenic peptide he would consider for minor, low-blood-flow injuries, while worrying about cancer if used preventatively. Attia and Munro then wrap up and outline topics for a part two.
- •BPC-157 is thought to be pro-angiogenic, and the bro advice to inject at the injury site is doubtful
- •Munro worries about its link to VEGF and cancer, especially with preventative use
- •A rigorous study is unlikely because of money and widespread use
- •Part two ideas include nutrition, appetite, fat loss, and spotting charlatans
- •Munro adds fertility protocols and the nuance of whether someone needs TRT
